规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | Carbonic Anhydrase ↓ ↑ | Carbonic Anhydrase I ↓ ↑ | Carbonic Anhydrase II ↓ ↑ | Carbonic Anhydrase IV ↓ ↑ | Carbonic Anhydrase IX ↓ ↑ | Carbonic Anhydrase XII ↓ ↑ | 其他靶点 | 纯度 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Topiramate | ✔ | Calcium Channel | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Dichlorphenamide | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Mafenide Acetate | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Benzenesulphonamide | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Dorzolamide HCl |
+
Carbonic anhydrase I, Ki: 6000 nM |
++++
Carbonic anhydrase II, Ki: 1.9 nM |
+++
Carbonic anhydrase IV, Ki: 31 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Methazolamide |
++
hCAI, Ki: 50 nM |
+++
hCAII, Ki: 14 nM |
++
bCAIV, Ki: 36 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Tioxolone |
+
CAI, Ki: 91 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
U-104 |
++
CAIX, Ki: 45.1 nM |
++++
CAXII, Ki: 4.5 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | hCAI/II-IN-6, an orally active human carbonic anhydrase (CA) inhibitor, selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5, and >50000 nM for hCA I, hCA II, hCA VII, and hCA XII, respectively. It exhibits anticonvulsant and anti maximal electroshock (MES) activities in vivo, suitable for epilepsy research [1]. |
体内研究 | hCAI/II-IN-6, administered intraperitoneally at doses ranging from 30 to 100 mg/kg once, exhibits significant anticonvulsant efficacy in vivo [1]. HCAI/II-IN-6, administered orally at a dose of 30 mg/kg once, demonstrates anti-maximal electroshock (MES) activityin vivo[1]. |
体外研究 | hCAI/II-IN-6 inhibits the activities of hCA I, hCA II, hCA VII, and hCA XII with Ki values of 220, 4.9, 6.5, and >50000 nM, respectively, in the concentration range of 0-50 μM [1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.57mL 0.51mL 0.26mL |
12.87mL 2.57mL 1.29mL |
25.74mL 5.15mL 2.57mL |
CAS号 | 694466-00-7 |
分子式 | C19H24N4O3S |
分子量 | 388.484 |
别名 | |
运输 | 蓝冰 |
存储条件 |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
DMSO: 250 mg/mL(643.53 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |